Genomictree Inc

Genomictree Inc has a highly liquid capital structure, with cash and equivalents amounting to KRW 16,314,618,920, representing 13.5% of total assets. The company's liquidity FPT (free cash flow to total assets) is negative at -8.99%, indicating ongoing cash outflows from operations. The current ratio of 17.75 is significantly above the industry median, suggesting strong short-term liquidity. Profitability metrics are negative, with a return on equity (ROE) of -7.81% and return on assets (ROA) of -7.44%. These figures are well below the industry median for ROE and ROA in the Biotechnology & Medical Research sector. The company reported a net loss of KRW 8,985,720,500 and an operating loss of KRW 11,305,781,840 in the latest period, indicating a challenging operating environment. The company's revenue is concentrated in a single business line, genomic analysis and molecular diagnostics, with no disclosed geographic diversification. This lack of segment or geographic diversification increases exposure to sector-specific risks. The company's revenue of KRW 3,760,069,690 is modest relative to its asset base, suggesting underutilization of capital. Looking ahead, the company is expected to maintain a negative growth trajectory, with no disclosed revenue growth in the current fiscal year. The operating cash flow of -KRW 10,192,656,970 and free cash flow of -KRW 10,850,448,950 indicate ongoing cash burn. The capital expenditure of -KRW 2,745,492,880 suggests continued investment in infrastructure, but without a clear path to positive cash flow. Risk factors include a low liquidity risk score and low dilution potential, with no immediate filing-based flags detected. The company's debt-to-equity ratio of 0.02 is well below the industry median, indicating a conservative capital structure. However, the negative operating and net income raise concerns about long-term sustainability. Recent events include the continuation of clinical trials for molecular diagnostic products and ongoing genomic analysis using next-generation sequencing. No material regulatory or litigation events were disclosed in the latest filings.